ZYMVOL, the biotech company based in Barcelona, specialized in the design, development and application of molecular modelling software to enzyme discovery and optimization, has released ZYMEVOLVER 2.0., a new improvement of its in silico enzyme engineering software.

The company, a CataloniaBio & HealthTech member, developed this new version, which aims to tackle some of the most common challenges scientists face while conducting enzyme engineering projects. “It represents a significant improvement in our technology. Since the simulations are performed quicker, scientists will have more time to broaden the sequence space exploration (including long-range mutations) and suggest more mutations per round ...

Photo gallery

Professionals from Santa Creu and Sant Pau Hospital have shared different clinical needs identified in their day-to-day care with start-ups and companies from CataloniaBio  & HealthTech, to generate synergies and develop joint solutions that reach healthcare professionals. and patients as soon as possible. The meeting took place in the Sala Antic Convent, in the Hospital de Sant Pau, within framework of the Hospital Connection event, on November 30. The conference is an initiative of the Innovation  Working Group of CataloniaBio & HealthTech, this time in collaboration with the IIB Sant Pau.

The presentation of the Technology and Innovation ...

DevsHealth has announced The Hacking Bacteria’s Project, which aims to in kind invest up to one million euros on antibiotics’ R&D projects during next three years. With this project, the new CataloniaBio &HealthTech member will collaborate with biotech and pharma companies as well as academic research groups to use its technology and expertise to boost antibiotic development projects. 

Each year, 330,000 people die from an infection due to bacteria resistant to antibiotics, a number that is expected to grow up to 10 million a year by 2050. Invest in antibiotics development is not profitable for pharmaceutical companies ...

ONA Therapeutics, the biotech member of CataloniaBio & HealthTech which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, announced the appointment of Dr Michel Detheux as Independent Chair to its Board of Directors.

Dr Michel Detheux is a veteran biotech executive with 25 years’ experience within the industry. He is currently the President and CEO of iTeos Therapeutics (NASDAQ:ITOS), a clinical stage, publicly-traded biotech company developing novel immuno-oncology therapies focused on key mechanisms of immunosuppression. Dr Detheux has spearheaded several capital raises and transactions for iTeos, including an initial public ...

The biotechnology company Oxolife has initiated a triple internacional collaboration with the Energy Balance, Puberty and Reproductive Health research group of the University of Cordoba (UCO, Spain) and the Human Growth and Reproductive Development research group at Rutgers, The State University of New Jersey. The main objective is to further investigate the direct mechanisms of the drug OXO-001, designed to improve embryo implantation and to treat infertility associated with Polycystic Ovary Syndrome (PCOS).

Oxolife, a CataloniaBio  & HealthTech member, is developing OXO-001, an innovative and pioneering drug for reproductive medicine. Oxolife  has already initiated a Phase II clinical trial ...

2021 is a year of celebration for Sensofar, they have  been in business for 20 years. They are a leading-edge technology group within the surface optical metrology field, and CataloniaBio & HealthTech  members.

 Roger Artigas, president of Sensofar Metrology, said “Our industry has progressed over the past 20 years in all areas out of the academy fields. Sensofar has played a large role in the defining key moments of optical metrology, and we are proud of our achievements. Optical metrology has become one of the most important phases in quality processes, and our profilometers are the most versatile equipment ...

The biotechnology company Vytrus Biotech, member of CataloniaBio &  HealthTech, has officially presented their corporate social responsibility project. The company, specializing in cosmetic active ingredients derived from plant stem cells,  recently received the Ecovadis Platinum Medal for CSR and sustainability.

The Vytrus CSR project, which began with our foundation 12 years ago, goes beyond any current trend and is explained by the awareness of the founders and by our own activity. The raw material, plants, and the technology, biotechnology, gives a focus on respect for nature and the environment, promoting values such as sustainability, social awareness, transparency and honesty, which ...

DyCare, a company specialized in developing medical solutions and a CataloniaBio & HealthTech member, has launched a free version of ReHub aimed at all rehabilitation professionals. ReHub is a telerehabilitation technology platform, designed to help improve the therapeutic results in musculoskeletal injuries.

The platform, now available in a free trial version, allows rehabilitators or physiotherapists to design therapeutic exercises that are 100% adapted to the needs of patients, who are the centre of recovery and offers them the possibility to carry out exercises at any given time and at any given time.

ReHub is currently being used in centres like ...

Photo  Gallery

The reindustrialization of the biomedical sector has been the focus of debate at the 2021 UnConference, from an inclusive approach where both large corporations, and SMEs and start-ups have played a leading role. CataloniaBio & HealthTech has brought together a hundred CEOs, executives, and entrepreneurs from pharmaceutical, biotechnology, medical technology and digital health entities and companies to address one of the issues that the pandemic has also brought back to the table.

The UnConference has become the main event of 2021 for CataloniaBio & HealthTech, after Covid-19 disrupted the other main events. It hosted the 2021 BioSuccess Award ...

CataloniaBio & HealthTech has recognised ONA Therapeutics with the Biosuccess award 2021 for its consolidation, investment attraction and growth as a spin-off. The event took place during the UnConference, the annual day of debate on the future of healthcare solutions promoted by CataloniaBio & HealthTech.

ONA Therapeutics S.L. is a biotechnology company specializing in the discovery and development of new biological therapies aimed at metastasis initiating cells and lipid metabolism. Founded in 2019 by Valerie Vanhooren and Salvador Aznar-Benitah, it is a spin-off of the Catalan Institution for Research and Advanced Studies (ICREA) and the Barcelona Institute for Research ...

Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio. Sanifit, based in Palma (Spain) has had the backing of international and Spanish funds, among which are the CataloniaBio  & HealthTech members Alta Life Sciences, Ysios Capital and Healthequity, as well as Caixa Capital Risc, Columbus Venture Partners, and Innvierte from CDTI.

Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company’s portfolio of ...

Pedro Sánchez, the Spanish president, has announced the strategic project for economic recovery and transformation (PERTE) ‘Salud de Vanguardia’. The project will mobilize 1,469 million public and private investment between 2021 and 2023.

Of the neraly 1.5 billion euros provided for in the project, about 982 million will come  from the public sector and at least 487 million directly from the private  sector. The aim of PERTE is to strengthen the National Health System and position Spain in the innovation and development of advanced therapies.

The PERTE structures around four main objectives and five strategic lines. The objectives ...

Oncoheroes Biosciences Inc. (“Oncoheroes”), a biotech focused on advancing new therapies for childhood cancer and member  of CataloniaBio & HealthTech, has out-licensed worldwide the adult rights to Notable Labs, Inc. (“Notable”), a clinical-stage predictive precision medicine company. Under the terms of this agreement, Oncoheroes will retain the license for the development and commercialization of volasertib for pediatric cancers and continue its commitment towards childhood cancer. Notable will have exclusive rights to develop and commercialize volasertib in adult cancer indications. Financial details of this deal are not disclosed.

Volsertib is a medicine designed by Boehringer Ingelheim for acute myeloid leukemia ...

For the first time ever, Grifols has been included on the Dow Jones Sustainability World Index (DJSI World) while retaining its distinction on the Dow Jones Sustainability Europe Index (DJSI Europe).

Grifols, a CataloniaBio & HealthTech  member, is recognized among the top six biotechnology companies globally  and is the only European firm in its industry to join the DJSI World. This year, the number of companies assessed in this sector increased by 46%.

As co-CEOs Raimon Grifols and Víctor Grífols Deu observed, “Sustainability is a long-term commitment to which we have remained faithful since our origins. Grifols’ distinction on the ...

Bringing science and technology closer to the public and promoting scientific vocations among the youngest have been the two main objectives of Science Week in Catalonia since it started 26 years ago. After all this time, this is the  first time that activities have been offered by companies in the sector, and they have done so with the help of CataloniaBio & HealthTech.

What is the route the blood takes once it comes out of the donor’s arm? Now dozens of people know the answer, those who took part in the guided tours throughout  the morning of Saturday 13 ...

After successfully completing the first edition of the BIOMED ScaleUP  program, CataloniaBio & HealthTech has chosen the issue of scaling up companies in the sector to debate in the context of the CEO Council. A group of CEOs of CataloniaBio & HealthTech met at the Barcelona School of Management (UPF) on November 10 to discuss this aspect that is critical to our ecosystem.

The special guest of the session was Amit Jain, co-founder of Veersa, Inc., a medical technology company based in the United States, and a seasoned Senior Operating Executive with extensive experience in the Healthcare industry, including US ...

The pharmaceutical company Ferrer, a CataloniaBio & HealthTech  member, will invest 20 million euros in converting its dermocosmetics plant in Esplugues de Llobregat so that it can also produce liquid medicines.

In an interview with the EFE news agency, Mario Rovirosa, CEO of Ferrer, explained that the company wants to further promote the brand's drugs, its  own innovation and focus on therapeutic areas such as neurology and pneumology. These are actions that Ferrer had stablished in his strategic plan until 2025, which has now been ratified and extended for the period 2022-2026.

The changes  at the Esplugues dermocosmetics plant is ...

Bringing science and technology closer to the public and encouraging scientific vocations among the youngest have been the two main objectives of Science Week in Catalonia since it started 26 years ago. After all this years, it will be the first time that companies  will participate with activities, and they will do so with the help of  CataloniaBio & HealthTech, with the members Ferrer and the Blood and Tissue  Bank.

The 2021 edition of the Science Week was presented this morning at an institutional event in the Parliament of Catalonia. "This participation is an opportunity to project companies in the ...

The biotechnology company, a member  of CataloniaBio & HealthTech, has been recognised this 2021 with the Ecovadis Platinum medal, the holistic platform for the qualification of CSR management and sustainability. By 2020 they had achieved the Ecovadis Silver in their first year of evaluation.

The Platinum  Medal is the highest grade and only 1% of companies evaluated worldwide receive  it. Vytrus has excelled in environmental and ethical issues, especially for its sustainability goals. This global recognition represents a further guarantee for Vytrus, the biotech company specializing in cosmetic active ingredients derived from plant stem cells.

For Albert  Jané, CEO ...

Veristat, a scientific-minded globalclinical research organization (CRO), announced the expansion of its regulatory services capabilities by acquiring Drug Development and Regulation (DDR), a scientific and regulatory consultancy with offices in Barcelona and Amsterdam, and a CataloniaBio & HealthTech member.

Led by Founder and Chief Executive Officer, Xavier Luria, M.D.— former Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) — DDR has carved out an impressive growth trajectory working with small to midsized companies largely involved in rare diseases and cancers, among others, and keenly interested in avoiding the implications of a less ...